The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Short-term patient-reported adverse events & HRQoL by CAR-T product in aggressive B-cell lymphomas
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, provides insight into a study that utilized real-world data to investigate short-term patient-reported adverse events and health-related quality of life (HRQoL) associated with CAR T-cell products in patients with aggressive B-cell lymphomas. The prevalence of short-term toxicity was higher than previously reported in the literature; however, Dr Efficace notes that the type of CAR T-cell product did not impact the prevalence of adverse events. The long-term effects of these CAR-T products on quality of life outcomes remain to be investigated. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Most of the studies that have been done in this population are actually based on clinical trials. So the patients that have been enrolled are actually selected patients. What we have done here in this observational study, so this is real-world data, we wanted to better understand what is short-term patient-reported toxicity. When I’m saying short-term, I’m referring to basically 10 days after infusion, and we wanted to see the prevalence of toxicity reported by these patients...
Most of the studies that have been done in this population are actually based on clinical trials. So the patients that have been enrolled are actually selected patients. What we have done here in this observational study, so this is real-world data, we wanted to better understand what is short-term patient-reported toxicity. When I’m saying short-term, I’m referring to basically 10 days after infusion, and we wanted to see the prevalence of toxicity reported by these patients. So we have seen that the prevalence is very high, much more than is actually reported in the literature. And but there are no differences compared to among different types of CAR T-cell products, so I guess this is an encouraging message for the hematology community. And we have seen also that the type of CAR T-cell product doesn’t have an impact on short-term quality of life. We don’t know yet what is the impact, if there is an impact, of different products in terms of long-term quality of life outcomes. We’re going to see this in future research.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
